Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Immune-mediated inflammatory diseases (IMIDs)"'
Autor:
Carlo Di Gregorio, Matteo Tretti-Clementoni, Magda Belmontesi, Marina Romagnoli, Alessandro Innocenti, Malvina Zanchi, Lucia Leone, Giovanni Damiani, Ivano Iozzo
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 7, Pp 1603-1610 (2023)
Abstract Introduction Randomized controlled trials (RCTs) suggested that liquid formulation of botulinum toxin type A (aboBoNT-A) is safe and effective, but data confirming these characteristics in a real-life heterogenous set of patients are current
Externí odkaz:
https://doaj.org/article/ab41658341574ae9adea7f58c287201c
Autor:
José M. Serra López-Matencio, Esther F. Vicente-Rabaneda, Estefanía Alañón, Ainhoa Aranguren Oyarzabal, Pedro Martínez Fleta, Santos Castañeda
Publikováno v:
Vaccines, Vol 11, Iss 12, p 1813 (2023)
The COVID-19 vaccination program has probably been the most complex and extensive project in history until now, which has been a challenge for all the people involved in the planning and management of this program. Patients with immune-mediated infla
Externí odkaz:
https://doaj.org/article/c627d2a03f4c423aa72f54395b6110fa
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immune-mediated inflammatory diseases(IMIDs) are referred to as highly disabling chronic diseases affecting different organs and systems. Inappropriate or excessive immune responses with chronic inflammation are typical manifestations. Usually in pat
Externí odkaz:
https://doaj.org/article/c3d35c65297646ed8ebaddf1b26009c7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Laixi Xue, K. van Bilsen, M. W. J. Schreurs, M. E. J. van Velthoven, T. O. Missotten, A. A. H. J. Thiadens, R. W. A. M. Kuijpers, P. van Biezen, V. A. S. H. Dalm, J. A. M. van Laar, M. A. W. Hermans, W. A. Dik, P. L. A. van Daele, P. M. van Hagen
Publikováno v:
Frontiers in Medicine, Vol 7 (2020)
Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were intro
Externí odkaz:
https://doaj.org/article/e152d3e8b46f4c7a951758b552d87606
Autor:
Charles Gwellem Anchang, Cong Xu, Maria Gabriella Raimondo, Raja Atreya, Andreas Maier, Georg Schett, Vasily Zaburdaev, Simon Rauber, Andreas Ramming
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 14, p 7506 (2021)
Immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel diseases and inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis), are marked by increasing worldwide incidence rates. Apart from irreversible damage of the
Externí odkaz:
https://doaj.org/article/ead5167c0e98474ba055c0bc2fd1f6b3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Salcines Rueda, Leticia
Publikováno v:
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Universidad de Cantabria (UC)
RESUMEN : La enfermedad inflamatoria intestinal (EII) comprende dos entidades, la enfermedad de Crohn (EC) y la colitis ulcerosa (CU). Estas enfermedades forman parte un grupo de patologías englobadas bajo el termino enfermedades inflamatorias inmun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::8c67b50b2c4b6106bc93d1ada502310a
http://hdl.handle.net/10902/23553
http://hdl.handle.net/10902/23553
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Laixi Xue, K. van Bilsen, M. W. J. Schreurs, M. E. J. van Velthoven, T. O. Missotten, A. A. H. J. Thiadens, R. W. A. M. Kuijpers, P. van Biezen, V. A. S. H. Dalm, J. A. M. van Laar, M. A. W. Hermans, W. A. Dik, P. L. A. van Daele, P. M. van Hagen
Publikováno v:
Frontiers in Medicine, 7:418. Frontiers Media S.A.
Frontiers in Medicine, Vol 7 (2020)
Frontiers in Medicine
Frontiers in Medicine, Vol 7 (2020)
Frontiers in Medicine
Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were intro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba65c21bf17d25fa1100bf43e3827798
https://pure.eur.nl/en/publications/007aabaf-4fdc-4242-9563-c99a7f4f8ee5
https://pure.eur.nl/en/publications/007aabaf-4fdc-4242-9563-c99a7f4f8ee5